Baseline ocular characteristics improve patient selection for ocriplasmin treatment

VANCOUVER, British Columbia — Specific baseline ocular characteristics can help to identify patients with vitreomacular adhesion resolution who can benefit from ocriplasmin treatment, according to a speaker here.

This sub-analysis of the phase 4, multicenter, prospective Ocriplasmin Research to Better Inform Treatment (ORBIT) study evaluated the effect of baseline ocular patient characteristics on the resolution of vitreomacular adhesion (VMA) and vitreomacular traction (VMT) in patients receiving ocriplasmin.